Prothena Corporation Plc (PRTA) 66.35 $PRTA 3 L
Post# of 273322
Posted On: 07/29/2015 1:44:12 PM
Prothena Corporation Plc (PRTA) 66.35 $PRTA
3 Long Shots Biotech Companies Are Working On
Todd Campbell, The Motley Fool - Motley Fool - Fri Jul 10, 4:04PM CDT
Source: Flickr user Micolo J. The Holy Grail of biotech companies is a billion-dollar blockbuster therapy, but more often than not, efforts to invent game-changing medicines that can eclipse the billion-dollar threshold fall short. That's...
BIIB: 311.57 (-8.36), PRTA: 66.35 (-2.35)
Why Shares of Prothena Surged 33% Higher in June
Todd Campbell, The Motley Fool - Motley Fool - Sat Jul 04, 10:02AM CDT
Source: Prothena Corp. Plc Compelling early stage trial data for Prothena Corp. Plc 's PRX002 as a therapy for Parkinson's disease sent the company's shares soaring 33.5% in June. Offering new hope Prothena is developing PRX002 with ...
PRTA: 66.35 (-2.35)
10 Best Biotech Stocks in the NASDAQ
at The Street - Wed Jul 01, 10:23AM CDT
The biotech sector has been one of the fastest growing sectors through June 30, 2015. Here are the 10 best biotech stocks this year.
SGYP: 8.13 (-0.11), HALO: 23.25 (-0.46), RARE: 117.45 (-3.15), KYTH: 74.49 (-0.03), RTRX: 31.70 (-1.33), IMGN: 17.62 (-0.48), HZNP: 36.68 (-1.64), ANAC: 147.93 (-3.38), PRTA: 66.35 (-2.35), EXEL: 5.66 (+0.25)
Prothena Announces Addition of Seasoned Executive to Board of Directors
Thomson Reuters ONE - Mon Jun 29, 3:05PM CDT
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
PRTA: 66.35 (-2.35)
5 Stocks Leading XBI Biotech ETF Higher
Zacks Funds - Seeking Alpha - Fri Jun 26, 5:09AM CDT
The biotech corner of the health care space is having a stellar run like last year and still remains a favorite investment destination for investors. This is primarily thanks to strong earnings growth, merger & acquisition frenzy, promising drug...
HRTX: 32.73 (-1.16), XBI: 252.10 (-6.84), RTRX: 31.70 (-1.33), EGRX: 92.18 (-0.66), PRTA: 66.35 (-2.35), EXEL: 5.66 (+0.25)
5 Stocks Leading XBI Biotech ETF Higher - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Thu Jun 25, 9:30AM CDT
These five stocks have contributed much to the outstanding performance of this biotech ETF.
HRTX: 32.73 (-1.16), XBI: 252.10 (-6.84), RTRX: 31.70 (-1.33), EGRX: 92.18 (-0.66), PRTA: 66.35 (-2.35), EXEL: 5.66 (+0.25)
Seeking Alpha's Biotech Weekly: Bubble Trouble, Allergan's Kythera Takeout, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Jun 19, 3:08PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
AGN: 337.97 (-1.53), ACAD: 48.14 (-1.16), KYTH: 74.49 (-0.03), TKMR: 10.27 (unch), AMGN: 169.91 (-2.83), AERI: 18.46 (-0.68), TEVA: 71.05 (-0.36), LLY: 85.06 (-0.62), PRTA: 66.35 (-2.35), NVS: 103.78 (+0.99), HCC: 77.18 (-0.07)
The Makings Of A Biotech Bubble
Bret Jensen - at Seeking Alpha - Wed Jun 17, 12:06PM CDT
AGEN: 8.17 (-0.16), CRIS: 3.13 (-0.04), TTPH: 46.89 (-1.46), XBI: 252.10 (-6.84), IBB: 376.44 (-6.40), ABBV: 71.38 (+0.15), EGRX: 92.18 (-0.66), PRTA: 66.35 (-2.35), CELG: 132.90 (-2.52)
Prothena's PRX002 knocks down PD-related protein 96% in early stage study
Seeking Alpha - at Seeking Alpha - Wed Jun 17, 7:15AM CDT
PRTA: 66.35 (-2.35)
Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002...
Thomson Reuters ONE - Wed Jun 17, 6:00AM CDT
- PRX002 was Safe and Well Tolerated; Phase 1 Single Ascending Dose Study Objectives Met
PRTA: 66.35 (-2.35)
Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002, Novel Protein Immunotherapy for Parkinson's Disease
GlobeNewswire - Wed Jun 17, 6:00AM CDT
-- PRX002 was Safe and Well Tolerated; Phase 1 Single Ascending Dose Study Objectives Met
PRTA: 66.35 (-2.35)
Prothena to Present at JMP Securities Life Science Conference 2015 on June 23
Thomson Reuters ONE - Tue Jun 16, 3:06PM CDT
DUBLIN, Ireland, June 16, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq
RTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that members of the senior management team will present and participate in investor meetings at the JMP Securities Life Science Conference 2015 on June 23 at 10 a.m. EDT at The St. Regis in New York, NY.
PRTA: 66.35 (-2.35)
Prothena's NEOD001 Protein Immunotherapy Clinical Data Highlighted in Oral Presentation at the 20th Congress of the European Hematology Association
Thomson Reuters ONE - Fri Jun 12, 6:05AM CDT
DUBLIN, Ireland, June 12, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NasdaqRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that Dr. Michaela Liedtke of Stanford University School of Medicine presented data from the ongoing Phase 1/2 trial of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction in an oral presentation (Abstract #S104) during the 20th Congress of the European Hematology Association (EHA) in Vienna.
PRTA: 66.35 (-2.35)
Opportunity to Improve Diagnosis and Treatment of Systemic Amyloidosis Highlighted in Patient Experience Survey Presented at the 20th Congress of the European Hematology Association
Thomson Reuters ONE - Fri Jun 12, 6:00AM CDT
- 72% of Survey Respondents had AL Amyloidosis
PRTA: 66.35 (-2.35)
Prothena (PRTA) Starts Phase I Study on Psoriasis Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 10, 2:35PM CDT
Prothena Corporation plc (PRTA) dosed the first patient in a phase I study on PRX003 for the potential treatment of psoriasis and other inflammatory diseases.
VRX: 254.49 (-3.46), PRTA: 66.35 (-2.35)
3 Long Shots Biotech Companies Are Working On
Todd Campbell, The Motley Fool - Motley Fool - Fri Jul 10, 4:04PM CDT
Source: Flickr user Micolo J. The Holy Grail of biotech companies is a billion-dollar blockbuster therapy, but more often than not, efforts to invent game-changing medicines that can eclipse the billion-dollar threshold fall short. That's...
BIIB: 311.57 (-8.36), PRTA: 66.35 (-2.35)
Why Shares of Prothena Surged 33% Higher in June
Todd Campbell, The Motley Fool - Motley Fool - Sat Jul 04, 10:02AM CDT
Source: Prothena Corp. Plc Compelling early stage trial data for Prothena Corp. Plc 's PRX002 as a therapy for Parkinson's disease sent the company's shares soaring 33.5% in June. Offering new hope Prothena is developing PRX002 with ...
PRTA: 66.35 (-2.35)
10 Best Biotech Stocks in the NASDAQ
at The Street - Wed Jul 01, 10:23AM CDT
The biotech sector has been one of the fastest growing sectors through June 30, 2015. Here are the 10 best biotech stocks this year.
SGYP: 8.13 (-0.11), HALO: 23.25 (-0.46), RARE: 117.45 (-3.15), KYTH: 74.49 (-0.03), RTRX: 31.70 (-1.33), IMGN: 17.62 (-0.48), HZNP: 36.68 (-1.64), ANAC: 147.93 (-3.38), PRTA: 66.35 (-2.35), EXEL: 5.66 (+0.25)
Prothena Announces Addition of Seasoned Executive to Board of Directors
Thomson Reuters ONE - Mon Jun 29, 3:05PM CDT
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
PRTA: 66.35 (-2.35)
5 Stocks Leading XBI Biotech ETF Higher
Zacks Funds - Seeking Alpha - Fri Jun 26, 5:09AM CDT
The biotech corner of the health care space is having a stellar run like last year and still remains a favorite investment destination for investors. This is primarily thanks to strong earnings growth, merger & acquisition frenzy, promising drug...
HRTX: 32.73 (-1.16), XBI: 252.10 (-6.84), RTRX: 31.70 (-1.33), EGRX: 92.18 (-0.66), PRTA: 66.35 (-2.35), EXEL: 5.66 (+0.25)
5 Stocks Leading XBI Biotech ETF Higher - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Thu Jun 25, 9:30AM CDT
These five stocks have contributed much to the outstanding performance of this biotech ETF.
HRTX: 32.73 (-1.16), XBI: 252.10 (-6.84), RTRX: 31.70 (-1.33), EGRX: 92.18 (-0.66), PRTA: 66.35 (-2.35), EXEL: 5.66 (+0.25)
Seeking Alpha's Biotech Weekly: Bubble Trouble, Allergan's Kythera Takeout, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Jun 19, 3:08PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. See something here that deserves further analysis? We are always looking for new...
AGN: 337.97 (-1.53), ACAD: 48.14 (-1.16), KYTH: 74.49 (-0.03), TKMR: 10.27 (unch), AMGN: 169.91 (-2.83), AERI: 18.46 (-0.68), TEVA: 71.05 (-0.36), LLY: 85.06 (-0.62), PRTA: 66.35 (-2.35), NVS: 103.78 (+0.99), HCC: 77.18 (-0.07)
The Makings Of A Biotech Bubble
Bret Jensen - at Seeking Alpha - Wed Jun 17, 12:06PM CDT
AGEN: 8.17 (-0.16), CRIS: 3.13 (-0.04), TTPH: 46.89 (-1.46), XBI: 252.10 (-6.84), IBB: 376.44 (-6.40), ABBV: 71.38 (+0.15), EGRX: 92.18 (-0.66), PRTA: 66.35 (-2.35), CELG: 132.90 (-2.52)
Prothena's PRX002 knocks down PD-related protein 96% in early stage study
Seeking Alpha - at Seeking Alpha - Wed Jun 17, 7:15AM CDT
PRTA: 66.35 (-2.35)
Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002...
Thomson Reuters ONE - Wed Jun 17, 6:00AM CDT
- PRX002 was Safe and Well Tolerated; Phase 1 Single Ascending Dose Study Objectives Met
PRTA: 66.35 (-2.35)
Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002, Novel Protein Immunotherapy for Parkinson's Disease
GlobeNewswire - Wed Jun 17, 6:00AM CDT
-- PRX002 was Safe and Well Tolerated; Phase 1 Single Ascending Dose Study Objectives Met
PRTA: 66.35 (-2.35)
Prothena to Present at JMP Securities Life Science Conference 2015 on June 23
Thomson Reuters ONE - Tue Jun 16, 3:06PM CDT
DUBLIN, Ireland, June 16, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq
RTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that members of the senior management team will present and participate in investor meetings at the JMP Securities Life Science Conference 2015 on June 23 at 10 a.m. EDT at The St. Regis in New York, NY. PRTA: 66.35 (-2.35)
Prothena's NEOD001 Protein Immunotherapy Clinical Data Highlighted in Oral Presentation at the 20th Congress of the European Hematology Association
Thomson Reuters ONE - Fri Jun 12, 6:05AM CDT
DUBLIN, Ireland, June 12, 2015 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq
RTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs, today announced that Dr. Michaela Liedtke of Stanford University School of Medicine presented data from the ongoing Phase 1/2 trial of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction in an oral presentation (Abstract #S104) during the 20th Congress of the European Hematology Association (EHA) in Vienna. PRTA: 66.35 (-2.35)
Opportunity to Improve Diagnosis and Treatment of Systemic Amyloidosis Highlighted in Patient Experience Survey Presented at the 20th Congress of the European Hematology Association
Thomson Reuters ONE - Fri Jun 12, 6:00AM CDT
- 72% of Survey Respondents had AL Amyloidosis
PRTA: 66.35 (-2.35)
Prothena (PRTA) Starts Phase I Study on Psoriasis Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 10, 2:35PM CDT
Prothena Corporation plc (PRTA) dosed the first patient in a phase I study on PRX003 for the potential treatment of psoriasis and other inflammatory diseases.
VRX: 254.49 (-3.46), PRTA: 66.35 (-2.35)
(0)
(0)